What is Altimmune?
Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to creating treatments for obesity and liver diseases. Its primary focus is on pemvidutide, a dual GLP-1/glucagon receptor agonist currently in Phase 2 trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company is also advancing HepTcell, an immunotherapeutic candidate for chronic hepatitis B virus infection, which is also in Phase 2 development. Formerly known as Vaxin Inc., Altimmune was founded in 1997 and is headquartered in Gaithersburg, Maryland.
How much funding has Altimmune raised?
Altimmune has raised a total of $296.1M across 5 funding rounds:
Multiple Rounds
$66M
Debt
$350K
Grant
$4.7M
Private Equity (2015): $8M with participation from Truffle Capital, Bonaventure Capital, HealthCap Partners, and Novartis Venture Fund
Share Placement (2015): $16M led by Truffle Capital, Bonaventure Capital, HealthCap Partners, and Novartis Venture Fund
Private Equity (2015): $42M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Grant (2020): $4.7M backed by U.S. Army Medical Research & Development Command
Key Investors in Altimmune
Truffle Capital
Truffle Capital is a leading European Business Builder focused on BioMedTech and Fintech, known for financing innovation and supporting pioneering technologies. They specialize in creating and developing companies that aim to become leaders in their sectors, with a strong emphasis on addressing unmet medical needs.
Bonaventure Capital
Bonaventure Capital is a strategic investment firm that partners with founders to provide capital and strategic support. They focus on companies addressing real-world challenges and emphasize sustainable growth, offering tailored investment solutions.
HealthCap Partners
HealthCap Partners is a private equity firm specializing in growth capital and real estate solutions for the healthcare industry. They assist operating partners by providing capital for growth, buy-outs, recapitalizations, and strategic real estate initiatives.
What's next for Altimmune?
With the recent major strategic investment, Altimmune is poised to further its clinical development programs. The company's focus on addressing significant unmet needs in obesity and liver disease positions it for substantial growth. Continued progress in its Phase 2 trials for pemvidutide and HepTcell will be critical in attracting further investment and potentially leading to commercialization. The enterprise-level backing suggests confidence from investors in Altimmune's long-term strategy and therapeutic potential.
See full Altimmune company page
